Biotech Holdings Announces Positive Preclinical Results on ProCell Probiotic Cell Therapy for Critical Limb Ischemia

SAN DIEGO, June 1, 2016 /PRNewswire/ -- Biotech Holdings announced today positive preclinical results utilizing its ProCell Therapy Protocol on the treatment of ischemic muscular disease. ProCell was effective at preventing limb loss in an aggressive model of peripheral artery disease which resembles critical limb ischemia, a condition that causes 250,000 amputations per year.

ProCell is the first product combining cellular therapy and probiotic intervention, specifically it leverage the ability of proprietary probiotics to activate in patients a unique type of cell named the T regulatory cell. Biotech Holding possesses intellectual property covering the unique ability of the T regulatory cell to overcome lack of oxygen in different tissues.

"I am thankful for our collaborators who have assisted us in rapidly progressing the success of this program, which validated our hypothesis that T regulatory cells can be potent stimulators of angiogenesis," said Jessica Baker, CEO of Biotech Holdings. "To our knowledge these data are the first to demonstrate that immune system cells can be used as drivers of new vessel production."

Historically stem cells have been used for stimulation of new blood vessel production. The novel data presented suggests that immune system cells can be used as a potential replacement. Immune system cells useful for producing new blood vessels are difficult to grow. The current data suggests that probiotics can overcome many of the hurdles associated with therapeutic utilization of T regulatory cells.

Contacts

Jessica Baker, MBA
Chief Executive Office
9255 Towne Centre Drive
#450
San Diego
CA 92121
619 609 3224

SOURCE Biotech Holdings